
CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number: 020974

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-974

MAR 9 1999

Lilly Research Laboratories
-Attention: Gregory T. Brophy, Ph.D.
Director, U.S. Regulatory Affairs
Lilly Corporate Center
Indianapolis, Indiana 46285

Dear Dr. Brophy:

Please refer to your new drug application (NDA) dated March 19, 1998, received March 20, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Prozac (fluoxetine HCl.) 10 mg and 20 mg Tablets.

We acknowledge receipt of your submissions dated June 5, July 7, July 30, August 4, August 24, September 21, September 29, November 17, November 20, November 23 1998, January 15, and February 18, 1999.

This new drug application provides for a new formulation, i.e., tablet dosage form, to this already marketed drug.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in your draft labeling submitted on March 19, 1998. Accordingly, the application is approved effective on the date of this letter.

We note that this labeling is identical to your currently approved labeling for Prozac capsules and solution except for revisions to the **Description** and **How Supplied** sections to provide for the new tablet formulation.

The final printed labeling (FPL) must be identical to your draft labeling (text for the package insert, immediate container and carton labels) submitted on March 19, 1998, along with incorporating the revision listed below. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

We additionally have the following comments pertaining to this application:

Chemistry and Manufacturing

1 Your response to our question regarding Method Validation is not acceptable. Specifically, the (b)(4)(TS)

laboratory for completion of the Methods Validation.

BEST POSSIBLE COPY

2. Please refer to the "**HOW SUPPLIED**" section of your proposed labeling submitted on March 19, 1998. Please revise the draft package insert such that the appropriate blister packaging is listed for the 20 mg tablet.
3. Please note that (b)(4)(CC) was sent an information request letter, and they have adequately responded to our inquiries regarding (b)(4)(CC)

Biopharmaceutics

Based on the individual dissolution data on both dosage strengths, i.e., 10 mg and 20 mg tablets, the dissolution method proposed in your application is acceptable, but the specifications should be set at:

Apparatus: USP Dissolution Apparatus I at 100 rpm
Media: Deaerated 0.1 N HCL of 1000 ml at 37°C
Specification: Q = (b)(4)(C) at 15 minutes

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 20-974." Approval of this submission by FDA is not required before the labeling is used.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Paul David, R.Ph., Regulatory Project Manager, at (301) 594-5530.

Sincerely,

(S)
[Redacted Signature]

5/9/99

Russell Katz, M.D.
Acting Director
Division of Neuropharmacological
Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research